Stopping imatinib in selected pediatric patients with chronic myeloid leukemia
Not Applicable
- Conditions
- Health Condition 1: C921- Chronic myeloid leukemia, BCR/ABL-positive
- Registration Number
- CTRI/2021/04/032690
- Lead Sponsor
- AIIMS
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
It will be a prospective observational study which will include patients diagnosed with CML in chronic phase with age less than or equal to 30 years at the time of diagnosis. Patients who are on imatinib for more than 3 years, and are in MMR for more than two years, imatinib will be stopped.
Exclusion Criteria
Patient age > 30 years
Patient diagnosed in CML AP/BP at baseline
Patient on imatinib less than 3 years
Patient in MMR for less than two years
Refusal of consent
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method